Kornimate/medical-research-clean huggingface dataset:
does oral intake decreases postoperative pain score in children

Conditions: Fasting; Postoperative Pain

Summary: pain score after inguinal hernia repair surgery in children decreased as time passed in previous studies. postoperative oral intake is usually resumed two hours after minor surgery in most of institutions, that may influence children's behavior and pain score. a recent study suggest that oral intake one hour after minor surgery does not increase the incidence of postoperative nausea and vomiting. the investigators primary endpoint is to clarify whether postoperative oral intake influences postoperative pain score in children.


Eligibility criteria:
inclusion criteria: * 18 month to 12 years old children undergoing elective unilateral inguinal hernia repair surgery exclusion criteria: * neurological disease, developmental delay
efficacy evaluation of collagen drink products

Conditions: Skin Condition

Summary: to assess maxi collagen drink on skin condition improvement


Eligibility criteria:
inclusion criteria: * healthy adults aged 35-65 years old exclusion criteria: * subject with skin surface damage larger than $50 coin area. * subject who had skin allergies caused by diet or undrwent cosmetic or medical treatment within 6 months. * subject who is a vegetarian and allergic to seafood, alcohol or listed ingredients in the product. * students who are currently taking courses taught by the principal investigator of this trial.
effects in the apob/apoa-i ratio using rosuvastatin and atorvastatin in patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to see if rosuvastatin compared to atorvastatin is effective in treating acs by decreasing the apob/apoa-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.


Eligibility criteria:
inclusion criteria: * hospital admission for acs with chest pain or discomfort occurring during rest or with minimal exertion, * percutaneous coronary intervention (pci) planned, * evidence of coronary artery disease exclusion criteria: * hypersensitivity to statins * any cholesterol lowering medication taken within 1 month prior v1 * sustained st-segment elevation on ecg
omega 3, leucine, probiotic lactobacillus paracasei ps23 on muscle mass in sarcopenic subjects

Conditions: Sarcopenia; Elderly; Omega 3

Summary: the purpose of the study is to evaluate the effect of supplementation with a nutritional blend based on omega 3 fatty acids, the probiotic leucine lactobacillus paracasei ps23 (olep), on muscle mass recovery in sarcopenic patients.


Eligibility criteria:
inclusion criteria: * sarcopenic patients (diagnosis made according to the criteria revised european consensus on definition and diagnosis) * body mass index between 20 and 30 kg/m2 exclusion criteria: * severe renal failure (glomerular filtration rate \< 30 ml/min) * moderate to severe liver failure (child-pugh class b or c) * endocrine diseases associated with calcium metabolism disorders (except osteoporosis) * known psychiatric disorders * cancer (over the past 5 years) * hypersensitivity to any component of the investigational nutritional supplement and * taking to protein/amino acid supplements (up to 3 months before starting the study) * patients unable to take oral therapy * receiving or with indication for artificial nutrition * who had been included in another clinical nutrition trial
protein digestion after bariatric surgery in older adults

Conditions: Overweight and Obesity; Bariatric Surgery Candidate; Aging; Protein Malabsorption

Summary: the goal of this clinical trial is to investigate protein digestibility after bariatric surgery. does protein digestibility decrease after roux-en-y-gastric bypass? does protein digestibility decrease after sleeve gastrectomy surgery? does protein digestibility effect the ability to meet protein requirements?

purpose of clinical trial is to investigate the digestion of dietary protein in older patients who have undergone roux-and-y bypass (rygb) or sleeve gastrectomy (sg) surgery. the primary objective is to compare dietary protein digestion during a test meal who have previously undergone a rygb surgery, sg surgery, or control patients, using a dual stable-isotope method. the secondary objectives are to investigate the relationship between protein intake corrected for protein digestion and skeletal muscle mass, and to investigate the relationship between the rate of free amino acid appearance and protein digestion.

Eligibility criteria:
inclusion criteria: * signed informed consent * group 1,2,3: age 65 years or older * group 4,5,6: age 18 to 65 years * group 1,2,4,5: previous bariatric surgery for obesity 1 - 10 years ago * group 3,6: no previous weight loss surgery exclusion criteria: * current diagnosis of cancer * advanced organ failure, including chronic kidney disease stage 5, liver cirrhosis stage 3, intestinal failure, heart failure stage d, or chronic obstructive pulmonary disease stage 4. * immobility * neuromuscular degenerative conditions * gastrointestinal conditions including coeliac disease, crohn's disease, previous resection of the small intestine, gastroparesis * unable to follow the procedures of the studies due to cognitive impairment such as diagnosed dementia. * allergy/intolerance to milk, or soy or spirulina
neurofeedback training (nft) on sleep quality and cognitive function performance among hiv-infected persons

Conditions: Poor Quality Sleep; HIV Infections

Summary: the purpose of this study is to evaluate the effects of nft on sleep quality and cognitive-behavioral performance among hiv-infected patients, to use it as a reference for the construction of nft as a clinical empirical treatment model for hiv-infected patients with sleep disturbance.

this study will aim to evaluate the effects of nft on sleep quality and neurocognitive performance among hiv-infected persons with sleep disturbance. a double-blind clinical randomized parallel trial will be enrolled in hiv-infected persons with sleep disturbance. we will exclude subjects with osa. random sampling by using a computer, and then we will be divided subjects into 2 groups. 30 people will be drawn into the experimental group and control group (sham). two groups will be treated with nft three times a week for at least four weeks. the vague distribution of this study will be handled by snose (sequentially numbered, opaque, sealed envelopes). double-blind subjects include subjects, family members, outcome appraisers, and technologists to ensure the integrity of randomized controlled trials and blind assignment. the outcome indicators are sleep quality and the chinese montreal cognitive assessment (moca). treatment compliance, sample loss, and adverse event events will be monitored, and the analysis will be followed the principle of intention to treat. the pair student t or mcnemar's test will use to test the effect of nft on sleep quality and neurocognitive performances among hiv-infected persons.

Eligibility criteria:
inclusion criteria: * hiv-infected persons exclusion criteria: * patients with central neural infections * pregnant women * drug or alcohol abuse

Keywords: neurocognitive performance, neurofeedback training
post-contrast 3d se t1 versus coronal se t1-wi mri in detecting optic neuritis (cocon)

Conditions: Optic Neuritis; Multiple Sclerosis

Summary: 3d flair, 3d t1 fat sat, coronal t2 and coronal t1 dixon sequences were usually used to assess visual deficits in mri. optic nerve examination is preferably performed using a coronal t2 sequence in order to detect a hypersignal suggestive of inflammation whereas brain examination is preferably performed using a 3d t1 sequence to highlight signs of spatial dissemination and lesions suggestive of multiple slerosis (ms). no study has yet investigated the detection capabilities of 3d t1 for the detection of optic nerve inflammation. the objective of this retrospective study was to determine whether a single 3d t1 sequence allows simultaneous exploration of the optic nerve and the brain for the positive diagnosis of optic neuropathy and/or ms.


Eligibility criteria:
inclusion criteria: * age \> 18 years * decrease in visual acuity explored in mri between january 2018 and january 2020 exclusion criteria: * past history of episode of optic neuritis
the efficacy tretinoin cream in the treatment of axillary hyperpigmentation associated with acanthosis nigricans

Conditions: Acanthosis Nigricans; Hyperpigmentation

Summary: the goal of this randomized intra-individual design with a split-side axillary approach is to comparing the efficacy of 0.025% tretinoin cream against a cream-based formulation in the treatment of axillary hyperpigmentation associated with acanthosis nigricans. the main questions it aims to answer are: * the efficacy of 0.025% tretinoin cream and cream based in the treatment of axillary hyperpigmentation associated with acanthosis nigricans. * the safety of 0.025% tretinoin cream and cream based in the treatment of axillary hyperpigmentation associated with acanthosis nigricans. participants were randomly assigned to apply both 0.025% tretinoin cream and the cream-based product on opposing sides of the axillary region.

this study employed a randomized intra-individual design with a split-side axillary approach, comparing the efficacy of 0.025% tretinoin cream against a cream-based formulation. participants were randomly assigned to apply both 0.025% tretinoin cream and the cream-based product on opposing sides of the axillary region. the efficacy of treatment was assessed by mexameter (melanin index). the investigator's global evaluation (ige) and parent's global evaluation (pge) were also used to evaluate the overall success rate. the local safety was conducted for assessment of any cutaneous irritation. at each visit, the investigator graded the degrees of erythema, dryness, peeling, burning, and itching using a scale of 0 to 4. this study was followed for 4 visits, at the baseline, at week 2, 4 and 8.

Eligibility criteria:
inclusion criteria: * the participants aged over 18 years with bmi more than 25 kg/m2, axillary hyperpigmentation associated with acanthosis nigricans exclusion criteria: * vulnerable skin diseases * infectious skin diseases * other recent diseases involving the axillary * other serious medical disorders e.g. liver disease * any patients having received other therapies for up to 4 weeks prior to enrollment * photosensitive skin * immunocompromised host * pregnancy and lactation * receiving oral retinoids * axillary tattoo
nitric oxide administration for acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: this research project is an open-label, randomized study for the use of nitric oxide in pediatric patients with acute respiratory distress syndrome (ards). the study examines whether nitric oxide (no) treatment impacts the the p:f ratio (arterial partial pressure of oxygen (pao2) divided by fraction of inspired oxygen (fio2) in patients with ards. the goal of the study is to evaluate whether the order of no therapy will have any effect on response, and evaluate the characteristics of patients who respond to no compared to those who do not.

at low concentrations, nitric oxide(no) functions as a cellular messenger and regulator of microcirculation. no may have an important role in the pathogenesis of ards as well as its treatment. no may be primarily useful in improving matching of ventilation and perfusion in the lung. the aims of the study are to attempt to show that no will improve oxygenation as evidenced by improvement in pao2/fio2. secondary aims are to see if the improvement in oxygenation allows there to be decreased time on fio2\>0.60, evaluate whether the order of no therapy will have any effect on response, and evaluate the characteristics of patients who respond to no compared to those who do not. subjects will be randomized to receive either nitric oxide first (nitric oxide for the first 4 hours, then no intervention/no nitric oxide for the next 4 hours) or delayed treatment with nitric oxide (no intervention/no nitric oxide for the first 4 hours, then nitric oxide for the next 4 hours).. blood gases were monitored once an hour during study participation (total of 8 hours). final pao2/fio2 levels will be compared after 8 hours of study treatment in each group.

Eligibility criteria:
inclusion criteria: * patient is intubated and mechanically ventilated in the pediatric intensive care unit with a pao2/fio2 ratio less than or equal to 100, fio2 greater than or equal to 0.60, peep greater than or equal to 10, and a murray score greater than or equal to 2.5. exclusion criteria: * neonates (1 week to 28 days) and/or patients on extracorporeal membrane oxygenation

Keywords: acute respiratory distress syndrome ards nitric oxide
gemcitabine, trastuzumab, and pertuzumab in the treatment of metastatic her2-positive breast cancer after prior trastuzumab/pertuzumab, or pertuzumab based therapy

Conditions: Metastatic HER2-Positive Breast Cancer

Summary: the purpose of this study is to see if a combination of drugs can help to treat breast cancer. this is a phase ii study which will test whether this combination of drugs is effective and will provide further information on side effects and safety. a standard chemotherapy, gemcitabine, will be combined with 2 other drugs that target the her2 receptor. the her2 receptor is a growth protein on the surface of some breast cancer cells that provides messages telling the breast cancer cell to grow. the standard chemotherapy will be gemcitabine.. the other two drugs work against her2. one is called trastuzumab (herceptin) and it is commonly given to women with advanced and early her2 positive breast cancer. the other drug, pertuzumab (perjeta), is also given to women with advanced her2 positive breast cancer. the drugs in this study are each individually approved for the treatment of metastatic breast cancer. however, this study is looking at the effectiveness of gemcitabine with trastuzumab and pertuzumab when given to women who have advanced her2 positive breast cancer who have had prior trastuzumab + pertuzumab or pertuzumab-based therapy.


Eligibility criteria:
inclusion criteria: * age ≥ to 18 * stage iv her2 (+) breast cancer * histologically documented her2 (+) breast cancer as defined as ihc 3+ or fish amplification of ≥ 2.0 of primary or metastatic site; results from the local lab are acceptable. * lecog performance status 0 -1 * prior treatment with trastuzumab + pertuzumab (hp)-based therapy or pertuzumab-based in the neoadjuvantadjuvant, unresectable, locally advanced, or metastatic setting. * ≤ 3 prior chemotherapies in the metastatic setting. prior anthracycline, taxane, gemcitabine, and anti-her2 agents (i.e. trastuzumab, pertuzumab, lapatinib, neratinib, tdm-1, etc.) are allowed. if patients received prior gemcitabine, it could not have been combined with pertuzumab. patients should have progression of disease on current therapy. * measurable or non-measurable disease. * lvef ≥ 50% * hematologic parameters: white blood cell (wbc) count of ≥ 3000/ul, absolute neutrophil count (anc) ≥ 1000/ul, platelets ≥ 100,000/ul, hemoglobin ≥10.0 g/dl * non-hematologic parameters: bilirubin ≤ 1.5 mg/dl, ast/alt≤ 2.5 x upper limit of normal (uln), alkaline phosphatase ≤ 5 x uln. * creatinine ≤ 1.5 mg/dl * patients with "treated and stable" brain lesions of a duration of ≥ 2 months may be enrolled. exclusion criteria: * history of prior unstable angina, myocardial infarction, chf, uncontrolled ventricular arrhythmias within 12 months * history of prior ≥ g 3 hypersensitivity (hsr) or any toxicity to trastuzumab or pertuzumab that warranted permanent cessation of this agent * history of hepatitis b or c * pregnant patients

Keywords: gemcitabine, trastuzumab pertuzumab 14-124
trial of acupuncture pelvic and low back pain in pregnancy (medical and economical assessment)

Conditions: Disorder of Pregnancy

Summary: pelvic girdle and low back pain are common in pregnancy, and cause severe impairment in 10% of women. our hypothesis is that offering acupuncture in addition to standard care would reduce pain and impairment throughout pregnancy. 300 pregnant women from 5 maternity units will be randomized over a 3 year period to receive standard care or standard care plus acupuncture. main outcome will be the number of days during pregnancy with maximum pain ≤ 4/10. secondary outcomes will compare groups for an impairment score and for direct and indirect costs.

background. pelvic and low back pain (plbp) affects 30% of pregnant women for weeks or months, causing severe impairment in 10% of women. standard treatment, based on pain killers, postural recommendations, exercises, is of limited value. previous trials showed that adding acupuncture to standard treatment reduces pain and impairment in the short run. hypothesis providing acupuncture to pregnant women with plbp could reduce pain and impairment throughout pregnancy, thus reducing other direct and indirect cots related to plbp. primary outcome. number and % of days during pregnancy with maximum pain ≤ 4/10. secondary outcomes. pain scale 4 weeks after inclusion, mean oswestry disability score between inclusion and delivery, direct costs related to pregnancy care and pain management, indirect costs related to impairment throughout pregnancy and the immediate postpartum. method. multicenter randomized trial with parallel groups. intervention: 5 acupuncture sessions over 4 weeks, plus standard treatment. controls: standard treatment. analysis per pregnancy follow up: logbook kept by he patient plus analysis of obstetrical records. number of patients: 300 inclusion criteria: singleton uncomplicated 16-34 weeks pregnancy, with plbp \> 4/10 exclusion criteria obstetrical complication other than plbp, contra indication to acupuncture, sciatica, maternal age \< 18, no health insurance. duration. overall duration: 3 years and 6 months, inclusions over 3 years. duration of inclusion per patient: 2-26 weeks number of participating centers 5

Eligibility criteria:
inclusion criteria: * singleton uncomplicated 16-34 weeks pregnancy, with plbp \> 4/10 exclusion criteria: * obstetrical complication other than plbp, * contra indication to acupuncture, * sciatica * maternal age \< 18 * no health insurance.

Keywords: pregnancy acupuncture pelvic and low back pain impairment economic evaluation
healthy kids pilot

Conditions: Childhood Obesity

Summary: up to 30 parent/child dyads will be recruited to participate in an m-health intervention (delivered over smartphone, ipad/tablet, or desktop/laptop) to promote healthy behaviors and healthy weight among children and their parents.


Eligibility criteria:
inclusion criteria for child: * have at least one participating parent * have a bmi percentile \> 85 * be physically capable of exercise * be free of diseases that affect metabolism, body weight, and food intake, including type 1 or type 2 diabetes, hiv/aids, and cancer inclusion criteria for parent: * have a smartphone * be willing to use the smartphone for the mhealth intervention exclusion criteria for child: * significant cardiovascular disease or disorders via self-report from parent * other significant medical problems that would prevent them from engaging in regular physical activity.
intravitreous ranibizumab as adjunctive treatment for trabeculectomy in neovascular glaucoma

Conditions: Glaucoma, Neovascular

Summary: to evaluate the effects of intravitreal ranibizumab (ivr) as adjunctive treatment for trabeculectomy with mitomycin c (tmc) in neovascular glaucoma (nvg).

this is a prospective study of 15 consecutive eyes from 14 patients (one patients had nvg in both eyes at presentation.) with nvg presented at the department of ophthalmology, faculty of medicine siriraj hospital, mahidol university, bangkok, thailand between december 2008 and december 2009. each eye received ivr (0.5 mg/0.05 ml) 1 week before tmc. trabeculectomy was performed with fornix-based conjunctival flap method.

Eligibility criteria:
inclusion criteria: * consecutive patients with neovascular glaucoma * age more than 80 year old * provide written informed consent exclusion criteria: * un-cooperated patients

Keywords: angiogenesis inhibitors neovascular intraocular pressure retinal vein occlusion vascular endothelial growth factor
a safety and pharmacokinetic study with cvx-045 in patients with advanced solid tumors

Conditions: Advanced Solid Tumors; Neoplasms; Carcinoma; Cancer; Malignancy

Summary: the purpose of the study is to determine safety and tolerability of cvx-045 in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * confirmed advanced solid tumors unresponsive to currently available therapies, or for which there is no standard therapy. * adequate coagulation, liver and renal function. * candidate for dce-mri evaluation. * ecog (eastern cooperative oncology group) performance status 0 or 1. exclusion criteria: * evidence of bleeding problems. * uncontrolled hypertension. * certain gastrointestinal problems including fistula and abscess. * patients with primary brain cancer.

Keywords: phase 1 solid tumors cvx-045
psychological context effects

Conditions: Positive Communication (Primary); Negative Communication; Control Condition

Summary: this study explores how contextual effects in the fore of positive and negative communication can affect the effect of an osteopathic technique on pain pressure thresholds.


Eligibility criteria:
inclusion criteria: * health volunteers with no forms of existing pain. exclusion criteria: * participants with existing pain.

Keywords: contextual effects
right: rhythm id going head-to-head trial

Conditions: Tachycardia

Summary: right is a randomized, prospective, two-arm study that will assess the differential efficacy of vitality 2 implantable cardioverter defibrillators (icds) using rhythm id™ versus selected medtronic icds.

right will compare the incidence of ventricular tachycardia/fibrillation (vt/vf) therapies delivered for supraventricular tachycardia (svt) episodes using vitality 2 devices with rhythm id™ to that of icds employing other rhythm discrimination algorithms. appropriateness of therapies will be assessed after independent adjudication of all vt/vf events leading to therapy. comparisons will be made between device manufacturers across patient populations receiving either a dual- or single-chamber device.

Eligibility criteria:
inclusion criteria: * patients who meet current indications for an icd * patients who sign and date a patient informed consent form prior to the implant visit * patients who remain in the clinical care of the enrolling physician in approved centers * patients who are able to tolerate icd programming as specifically prescribed in the study protocol exclusion criteria: * patients who are in third degree heart block * patients whose life expectancy is less than 12 months * patients who have other cardiac surgeries or procedures planned but not yet performed during the duration of the study * patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study * patients who are younger than 18 years of age * patients who are mentally incompetent and cannot sign a patient informed consent form or comply with the study * patients who are pregnant or plan to become pregnant during the study